AMPK signaling is preserved in tissues from CR animals, maintaining the integrity of the energy metabolism and the efficiency of fat metabolism. AMPK Signaling, a fuel sensor and regulator, promotes ATP-producing and inhibits ATP-consuming pathways in various tissues.
AMP-activated protein kinase (AMPK) is a central regulator of cellular energy homeostasis, playing critical roles in regulating growth and reprogramming metabolism as well as in cellular processes including autophagy and cell polarity.
The kinase is activated in response to stresses that deplete cellular ATP supplies such as low glucose, hypoxia, ischemia, and heat shock. As a cellular energy sensor responding to low ATP levels, AMPK activation positively regulates signaling pathways that replenish cellular ATP supplies. For example, activation of AMPK enhances both the transcription and translocation of GLUT4, resulting in an increase in insulin-stimulated glucose uptake.
AMPK is a heterotrimeric protein complex that is formed by α, β, and γ subunits. Each of these three subunits take on a specific role in both the stability and activity of AMPK.
As the figure shows, AMPK activation works via direct phosphorylation of multiple enzymes directly involved in these processes as well as through transcriptional control of metabolism by phosphorylating transcription factors, co-activators, and co-repressors. Because of its role in regulating energy homeostasis, AMPK is considered a potential target in the development of new treatments for obesity, type 2 diabetes, the metabolic syndrome, and cancer.
AMPK was first regarded to link to cancer owing to the discovery that AMPK can mediate the tumor suppressive signaling of liver kinase B1 (LKB1) to the inhibition of mechanistic target of rapamycin complex 1 (mTORC1), which is activated in most cancers. And the LKB1-AMPK axis has been thought as a tumor suppressor pathway through the repression of mTOR1 since the discovery.
In cancer, the role of AMPK exhibts two opposite faces just like a double-edged sword. On one hand, AMPK can protect against cell damage due to oxidative stress, which in turn protects against cancer and tumor initiation. On the other, AMPK promotes energy/glucose uptake by the cells, which can be used by a tumor once it has formed. The activation of AMPK elicits the metabolism reprogramming, which is critical for cell survival during metabolic stress that often occur under pathophysiological conditions such as those observed in the tumor microenvironment.
In a word, AMPK activation is deemed beneficial for the prevention of cancer, but not for its treatment. On the contrary, AMPK inhibition may be helpful for treating established cancers as it can help inhibit the survival and adaptation of tumor stress.
Insulin resistance (IR), dysdunction of beta cell, increased hepatic glucose production are the hallmarks of Type II diabetes, which is a metabolic disease. Once sensing too low cellular energy levels, AMPK is activated and signals to promote glucose uptake in skeletal muscles, fatty acid oxidation in adipose tissues, and decreases hepatic glucose synthesis. Accumulating data has shown that AMPK is out of regulation in animals and humans with Type II diabetes. And AMPK activation renders cells more sensitive to insulin and improves metabolic health.
Neurodegenerative disorders such as well-known Alzheimer's disease, Parkinson's disease, Huntington's disease, are characterized by nerve cells' progressive degeneration eventually resulting in dementia. These diseases share several features and signaling pathways. In particular, energy metabolism defects, oxidative stress, and excitotoxicity are commonly described and might be associated with AMPK deregulation. AMPK was hyperactive in the brain of patients affected by these neurodegenerative disorders. In response to certain cellular stressors, AMPK activation may exacerbate neuronal atrophy and cell death. AMPK is exactly implicated in the progression of these diseases.
|GYS1||GYS1 Antibody||GYS1 Protein||GYS1 cDNA||GYS1 ELISA Kit|
|GYS2||GYS2 Antibody||GYS2 Protein||GYS2 cDNA||GYS2 ELISA Kit|
|HMGCR||HMGCR Antibody||HMGCR Protein||HMGCR cDNA||HMGCR ELISA Kit|
|HNF4A||HNF4A Antibody||HNF4A Protein||HNF4A cDNA||HNF4A ELISA Kit|
|IGF1||IGF1 Antibody||IGF1 Protein||IGF1 cDNA||IGF1 ELISA Kit|
|IGF1R||IGF1R Antibody||IGF1R Protein||IGF1R cDNA||IGF1R ELISA Kit|
|INS||INS Antibody||INS Protein||INS cDNA||INS ELISA Kit|
|INSR||INSR Antibody||INSR Protein||INSR cDNA||INSR ELISA Kit|
|IRS1||IRS1 Antibody||IRS1 Protein||IRS1 cDNA||IRS1 ELISA Kit|
|IRS2||IRS2 Antibody||IRS2 Protein||IRS2 cDNA||IRS2 ELISA Kit|
|IRS4||IRS4 Antibody||IRS4 Protein||IRS4 cDNA||IRS4 ELISA Kit|
|LEP||LEP Antibody||LEP Protein||LEP cDNA||LEP ELISA Kit|
|LEPR||LEPR Antibody||LEPR Protein||LEPR cDNA||LEPR ELISA Kit|
|LIPE||LIPE Antibody||LIPE Protein||LIPE cDNA||LIPE ELISA Kit|
|MAP3K7||MAP3K7 Antibody||MAP3K7 Protein||MAP3K7 cDNA||MAP3K7 ELISA Kit|
|MLYCD||MLYCD Antibody||MLYCD Protein||MLYCD cDNA||MLYCD ELISA Kit|
|MTOR||MTOR Antibody||MTOR Protein||MTOR cDNA||MTOR ELISA Kit|
|PCK1||PCK1 Antibody||PCK1 Protein||PCK1 cDNA||PCK1 ELISA Kit|
|PCK2||PCK2 Antibody||PCK2 Protein||PCK2 cDNA||PCK2 ELISA Kit|
|PDPK1||PDPK1 Antibody||PDPK1 Protein||PDPK1 cDNA||PDPK1 ELISA Kit|